| Aug 13 |
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
|
| Aug 13 |
Lilly opens R&D hub; Ovid and Lexicon lay off staff
|
| Aug 7 |
Lexicon to present data on sotagliflozin for diabetes, kidney disease
|
| Aug 7 |
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
|
| Aug 7 |
Lexicon Pharmaceuticals Insider Buyers Pleased With US$724k Return On Investment
|
| Aug 3 |
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
|
| Aug 2 |
5 Analysts Have This To Say About Lexicon Pharmaceuticals
|
| Aug 2 |
Intel Reports Weak Results, Joins Amazon, Opendoor Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session
|
| Aug 2 |
Lexicon Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 2 |
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript
|
